HRS-6209
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for HRS-6209, covering 2025-06-22 to 2026-04-03. Get the full timeline:
Most recent: Clinical Trial Update: A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer [Phase 1, Phase 2]